Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented. We are presenting a patient with metastatic melanoma who develo...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open gastroenterology 2022-12, Vol.9 (1), p.e000989
Main Authors: Holmstroem, Rikke Boedker, Dahl, Emilie Kristine, Helms, Morten, Nielsen, Henrik Vedel, Andersen, Janne Bayer, Bjerrum, Jacob Tveiten, Svane, Inge Marie, Ellebaek, Eva, Seidelin, Jakob Benedict
Format: Article
Language:English
Subjects:
Antibiotics
Antineoplastic Agents, Immunological - adverse effects
Cancer therapies
Case reports
Colitis - drug therapy
Colitis - therapy
Cytokines
Diarrhea
Endoscopy
Enterocolitis - chemically induced
Enterocolitis - therapy
Fecal Microbiota Transplantation - adverse effects
Humans
Immunotherapy
Inflammatory Bowel Disease
Inhibitor drugs
Lymphocytes
Melanoma
Metastasis
Microbiota
Patients
Urinary tract diseases
Urinary tract infections
Urogenital system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented. We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib. This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.
ISSN:2054-4774
2054-4774
DOI:10.1136/bmjgast-2022-000989